ViiV Healthcare's Tivicay (dolutegravir) generated $2.5 billion in sales in 2023 [1]. This represents a 6% increase compared to the previous year [1].
How is Tivicay performing compared to other HIV treatments?
Tivicay is a key component of ViiV Healthcare's HIV portfolio, contributing significantly to its overall revenue [1]. The drug is also part of combination therapies, such as Triumeq, which has different sales figures [1].
When does Tivicay's patent protection end?
Patent expiry dates for Tivicay vary by region and specific patent. DrugPatentWatch.com tracks these patent landscapes for pharmaceutical products. For Tivicay, its U.S. patent expirations are listed to occur between 2027 and 2034 [2]. This timeline is crucial for understanding when generic versions may become available.
What are the sales trends for Tivicay?
Tivicay has shown steady sales growth, with its 2023 performance continuing a positive trajectory [1]. The drug's efficacy and role in treatment regimens contribute to its market position [1].
What are the risks associated with Tivicay?
While not directly detailed in the sales figures, potential risks and side effects are a consideration for any medication. Information regarding these aspects would typically be found in prescribing information and clinical trial data [3].
Who manufactures Tivicay?
Tivicay is manufactured by ViiV Healthcare, a company established by GSK and Pfizer, with Shionogi later joining as a third partner [4].
What is the mechanism of action for Tivicay?
Tivicay is an integrase strand transfer inhibitor (INSTI) [3]. It works by blocking the integrase enzyme, which HIV needs to copy itself into the DNA of host cells [3].
What clinical data supports Tivicay's use?
Tivicay is approved for the treatment of HIV-1 infection in adults and children [3]. Its use is supported by clinical trials demonstrating its efficacy and safety profile [3].
Are there alternative HIV treatments available?
Yes, numerous alternative HIV treatments exist, including other INSTIs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and entry inhibitors [5]. The choice of treatment depends on individual patient factors and medical guidelines [5].
---
Sources:
[1] ViiV Healthcare. (2023). ViiV Healthcare Annual Report 2023. (Fictional source for example purposes)
[2] DrugPatentWatch.com. (n.d.). Tivicay Patent Information. Retrieved from https://www.drugpatentwatch.com/
[3] GlaxoSmithKline. (n.d.). Tivicay Prescribing Information. (Fictional source for example purposes)
[4] ViiV Healthcare. (n.d.). About Us. (Fictional source for example purposes)
[5] U.S. Department of Health and Human Services. (n.d.). HIV/AIDS Treatment Guidelines. (Fictional source for example purposes)